Look Towards A New Future

May 6, 2012

Treatment Algorithms: Rectal Cancer

The rectal cancer pipeline has grown as pharmaceutical companies are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral part of treatment, but with key brands expected to come off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve.
Features and benefits
  • Disease overview assessing, etiology, risk factors, screening procedures, and patient segmentation
  • In-depth analysis of most common treatment types according to stage at diagnosis and patient characteristics
  • Analysis of physician prescribing trends in the seven major markets across all stages of disease
  • Analysis of possible future treatment trends with regard to targeted therapies and companion diagnostics
The standard of care for Stage I–III rectal cancer is based around surgical resection. The use of radiotherapy-based treatment increases with stage, with 66% of Stage IIIc patients treated with surgery and chemoradiation. However, Japanese physicians interviewed indicated that they did not use chemoradiation.
First-line treatment of metastatic rectal cancer is based on chemotherapy. Datamonitor’s survey indicated that 85% of Stage IV patients receive treatment containing chemotherapy, and 34% receive chemotherapy without any additional therapy. The use of chemoradiation in the first-line setting can impact treatment choices in the second-line.
Datamonitor’s survey indicated that the use of targeted therapies in the first- and second-line settings will increase. Increasing pressure to demonstrate cost-effectiveness of drugs and anticipated approval of new targeted therapies means the use of companion diagnostics will play an increasingly important role in the treatment of rectal cancer.

Buy Your Copy of Report @ 

Report Details:
Published: April 2012
No. of Pages: 52
 Price: Single User License: US $ 7600 Corporate User License : US $ 19000

Table of Contents
Strategic scoping and focus
Datamonitor key findings
Related reports
Disease definition
Colorectal cancer is the third most common tumor type and cause of cancer-related death in both men and women
The only differentiator between colon cancer and rectal cancer is primary tumor location
Adenomas are precursors to the majority of colorectal cancer cases
Inherited and environmental factors are instrumental in the etiology of colorectal cancer
Change in bowel habits is the principle symptom of colorectal cancer
Survival rates for colorectal cancer patients still lag behind those in other high-incidence indications
Presentation and diagnosis
Screening reduces colorectal cancer incidence and mortality
Influences on diagnosis and treatment rates
Screen for Life: National Colorectal Cancer Action Campaign
In 2012 the "Be clear on cancer" campaign was launched in the UK
Referral patterns
Referral is dictated by stage at diagnosis and treatment approach
Stage distribution
The American Joint Committee on Cancer TNM classification system has replaced the older Dukes' staging system
Overview of the available drug classes
Stage I–III
Treatment type
Chemotherapy prescribing trends
Chemoradiation prescribing trends
Stage IV
Treatment type
Prescribing trends: first line
Prescribing trends: second line and third line
Local and distant relapse
Local and distant relapse rates
Treatment and prescribing trends: local relapse
Treatment and prescribing trends: distant relapse
Future changes in therapy
Targeted therapies and companion diagnostics
Journal papers
Datamonitor reports
Physician data
Contributing experts
Conferences attended
Report methodology
List of Tables
Table: Rectal cancer 5-year survival rates by stage at diagnosis, 2001–07
Table: Leading treatments for rectal cancer across the seven major markets
Table: Percentage of patients receiving surgery, chemoradiation, and chemotherapy combined, in the seven major markets, 2011
Table: Survey respondents by country and physician type across the seven major markets, 2011